University College London Hospitals Collaborate with AstraZeneca and IgniteData to Test SMART ON FHIR Based Tech
University College London Hospitals NHS Foundation Trust, IgniteData and AstraZeneca have successfully gone live in non-production (a mirror image of the live health record with synthetic non-sensitive patient data) testing with IgniteData’s HL7 FHIR enabled clinical trial data transfer platform, Archer. Testing will be conducted on UCLH’s Epic non-production EHR, before going live during Q4 2021 to automate the transfer of data into AstraZeneca’s Medidata Rave for an oncology study.
During 2022, IgniteData will collaborate with AstraZeneca to scale the standardized technology to other NHS and European hospitals. Archer is supervised by the investigator, meaning they maintain full control of which data leaves the hospital and no sensitive data is retained by Archer.
The project does not involve any new sharing of data, beyond the planned data sharing that will occur in the oncology research study. The work with Archer aims to improve the way in which data is transferred between systems.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
